Stock Financial Ratios


KPTI / Karyopharm Therapeutics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price11.11
Volume94,300.00
Market Cap ($M)540.71
Enterprise Value ($M)356.62
Book Value ($M)162.24
Book Value / Share4.32
Price / Book3.83
NCAV ($M)163.91
NCAV / Share4.37
Price / NCAV3.67
Income Statement (mra) ($M)
Revenue0.15
EBITDA-110.73
Net Income-109.58
Balance Sheet (mrq) ($M)
Cash & Equivalents54.45
Cash / Share1.45
Assets163.77
Liabilities22.60
Quick Ratio7.99
Current Ratio7.99
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.68
Return on Assets (ROA)-0.61
Return on Equity (ROE)-0.68
Identifiers and Descriptors
CUSIP48576U106
Central Index Key (CIK)1503802
Industry Groups
SIC 2834 - Pharmaceutical Preparations
Other Related CUSIPS
48576U906
48576U956
Share Statistics
Common Shares Outstanding (M)47.18
Scoring Models
Piotroski F Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Property Plant And Equipment Net Per Share0.06
Inventory Work In Progress Per Share0.00
Retained Earnings Per Share-12.16
Property Plant And Equipment Gross Per Share0.12
Long Term Debt Per Share0.00
Treasury Stock Per Share0.00
Assets Current Per Share3.24
Debt Per Share0.00
Deferred Income Tax Liabilities Per Share0.00
Cash And Equivalents Per Share1.45
Cash Per Share1.45
Assets Other Non Current Per Share0.00
Liabilities Other Non Current Per Share0.00
Accumulated Depreciation And Depletion Per Share0.06
Intangibles Per Share0.00
Goodwill Per Share0.00
Liabilities Per Share0.60
Additional Paid In Capital Per Share15.93
Liabilities Current Per Share0.56
Assets Per Share4.36
Equity Per Share3.76
Minority Interest Per Share0.00
Property Plant And Equipment Per Share0.06
Current Portion Of Long Term Debt Per Share0.00
Accounts Receivable Per Share0.00
Inventory Raw Materials Per Share0.00
Liabilities And Stock Equity Per Share4.36
Assets Other Current Per Share0.00
Accounts Payable Per Share0.00
Inventory Finished Goods Per Share0.00
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Inventory Per Share0.00

Related News Stories

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-3)

Karyopharm Therapeutics' (KPTI) CEO Michael Kauffman on Q3 2017 Results - Earnings Call Transcript

2017-11-04 seekingalpha
Good morning. My name is Liz, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics Third Quarter 2017 Financial Results Conference Call. [Operator Instructions] Please be advised that this call's being recorded at the company's request. (1-0)

Your Daily Pharma Scoop: The First Trust NYSE Arca Biotechnology Index, Gilead's Single Pill, Acadia's New Trial

2017-10-05 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (578-4)

Cancer Space Update: Mixed Week for Pfizer, Roche Falters

2017-09-22 zacks
While last week was eventful with European Society for Medical Oncology (“ESMO”) congress taking place, this week saw the approval of Pfizer Inc.’s (PFE - Free Report) Bavencio in Europe. On the one hand, TESARO, Inc.’s (TSRO - Free Report) Zejula received positive CHMP opinion in the EU, while on the other, Pfizer’s Sutent got a mixed view from an FDA advisory committee for a label expansion application. (187-0)

Karyopharm's Liposarcoma Candidate Superior in Phase II Study

2017-09-21 zacks
Karyopharm Therapeutics Inc. (KPTI - Free Report) announced positive data from a phase II portion of phase II/III SEAL study, demonstrating superiority of its liposarcoma candidate, selinexor, in improving progression free survival (PFS) when compared to a placebo. The company’s oral Selective Inhibitor of Nuclear Export compound is being evaluated in patients with advanced unresectable dedifferentiated liposarcoma who have received prior treatment. (46-0)

CUSIP: 48576U106